Caricamento...
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
Insulin analog patent expiry is likely to mean that, increasingly, copies of original biopharmaceutical products will be submitted for authorization. Experience with biosimilars in other therapeutic areas suggests that careful regulation and caution are needed. Published guidelines of regulatory aut...
Salvato in:
| Pubblicato in: | Diabetes Technol Ther |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Mary Ann Liebert, Inc.
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4504437/ https://ncbi.nlm.nih.gov/pubmed/25789689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2014.0362 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|